title: Expression of membrane anchored cytokines and B7-1 alters tumor microenvironment and induces protective antitumor immunity in a murine breast cancer model.
abstract: Many studies have shown that the systemic administration of cytokines or vaccination with cytokine-secreting tumors augments an antitumor immune response that can result in eradication of tumors. However, these approaches are hampered by the risk of systemic toxicity induced by soluble cytokines. In this study, we have evaluated the efficacy of 4TO7, a highly tumorigenic murine mammary tumor cell line, expressing glycosyl phosphatidylinositol (GPI)-anchored form of cytokine molecules alone or in combination with the costimulatory molecule B7-1 as a model for potential cell or membrane-based breast cancer vaccines. We observed that the GPI-anchored cytokines expressed on the surface of tumor cells greatly reduced the overall tumorigenicity of the 4TO7 tumor cells following direct live cell challenge as evidenced by transient tumor growth and complete regression within 30 days post challenge. Tumors co-expressing B7-1 and GPI-IL-12 grew the least and for the shortest duration, suggesting that this combination of immunostimulatory molecules is most potent. Protective immune responses were also observed following secondary tumor challenge. Further, the 4TO7-B7-1/GPI-IL-2 and 4TO7-B7-1/GPI-IL-12 transfectants were capable of inducing regression of a wild-type tumor growing at a distant site in a concomitant tumor challenge model, suggesting the tumor immunity elicited by the transfectants can act systemically and inhibit the tumor growth at a distant site. Additionally, when used as irradiated whole cell vaccines, 4TO7-B7-1/GPI-IL-12 led to a significant inhibition in tumor growth of day 7 established tumors. Lastly, we observed a significant decrease in the prevalence of myeloid-derived suppressor cells and regulatory T-cells in the tumor microenvironment on day 7 post challenge with 4TO7-B7-1/GPI-IL-12 cells, which provides mechanistic insight into antitumor efficacy of the tumor-cell membrane expressed IL-12. These studies have implications in designing membrane-based therapeutic vaccines with GPI-anchored cytokines for breast cancer.
authors.affiliation: Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia 30322, United States. ebozema@emory.edu
authors.forename: Erica N
authors.initials: EN
authors.lastname: Bozeman
authors.forename: Ashley
authors.initials: A
authors.lastname: Cimino-Mathews
authors.forename: Deepa K
authors.initials: DK
authors.lastname: Machiah
authors.forename: Jaina M
authors.initials: JM
authors.lastname: Patel
authors.forename: Arun
authors.initials: A
authors.lastname: Krishnamoorthy
authors.forename: Linda
authors.initials: L
authors.lastname: Tien
authors.forename: Rangaiah
authors.initials: R
authors.lastname: Shashidharamurthy
authors.forename: Periasamy
authors.initials: P
authors.lastname: Selvaraj
mesh_terms: D000818:Animals; D018122:B7-1 Antigen / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D001943:Breast Neoplasms / Q000150:complications / Q000235:genetics / Q000276:immunology* / Q000473:pathology; D019496:Cancer Vaccines / Q000235:genetics* / Q000276:immunology* / Q000378:metabolism; D002462:Cell Membrane / Q000378:metabolism*; D016207:Cytokines / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D017261:Glycosylphosphatidylinositols / Q000378:metabolism; D018664:Interleukin-12 / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D007376:Interleukin-2 / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D051379:Mice; D008807:Mice, Inbred BALB C; D022423:Myeloid Cells / Q000166:cytology / Q000276:immunology; D012995:Solubility; D013163:Splenomegaly / Q000150:complications; D050378:T-Lymphocytes, Regulatory / Q000276:immunology / Q000378:metabolism; D014162:Transfection; D047368:Tumor Burden; D059016:Tumor Microenvironment / Q000276:immunology*
chemical_list: D018122:B7-1 Antigen; D019496:Cancer Vaccines; D016207:Cytokines; D017261:Glycosylphosphatidylinositols; D007376:Interleukin-2; D018664:Interleukin-12
references.citation: J Transl Med. 2012 Apr 10;10:70
references.pmid: 22490302
references.citation: Blood. 1997 Oct 1;90(7):2541-8
references.pmid: 9326219
references.citation: Curr Opin Investig Drugs. 2009 Dec;10(12):1315-24
references.pmid: 19943203
references.citation: J Pathol. 2011 Jul;224(3):389-400
references.pmid: 21437909
references.citation: Int J Cancer. 2005 Nov 20;117(4):538-50
references.pmid: 15912538
references.citation: Anticancer Res. 2009 Mar;29(3):881-8
references.pmid: 19414323
references.citation: Clin Cancer Res. 2008 Apr 15;14(8):2413-20
references.pmid: 18413832
references.citation: J Clin Oncol. 1991 Apr;9(4):694-704
references.pmid: 2066765
references.citation: Proc Natl Acad Sci U S A. 1978 Jun;75(6):2844-8
references.pmid: 351618
references.citation: Proc Natl Acad Sci U S A. 1993 Apr 15;90(8):3539-43
references.pmid: 8097319
references.citation: Cancer Gene Ther. 2001 May;8(5):361-70
references.pmid: 11477456
references.citation: Clin Cancer Res. 2009 Feb 1;15(3):971-9
references.pmid: 19188168
references.citation: Am J Pathol. 2004 Dec;165(6):1853-63
references.pmid: 15579430
references.citation: Cancer Res. 2012 Oct 1;72(19):4875-82
references.pmid: 23002210
references.citation: Proc Natl Acad Sci U S A. 1995 Aug 15;92(17):8059-63
references.pmid: 7544014
references.citation: Proc Natl Acad Sci U S A. 2010 Dec 14;107(50):21248-55
references.pmid: 21081700
references.citation: Int Immunopharmacol. 2007 Feb;7(2):140-51
references.pmid: 17178380
references.citation: CA Cancer J Clin. 2012 Jan-Feb;62(1):10-29
references.pmid: 22237781
references.citation: Cancer Res. 2005 Sep 15;65(18):8059-64
references.pmid: 16166275
references.citation: J Immunol Methods. 2003 Aug;279(1-2):123-33
references.pmid: 12969553
references.citation: Cell. 2011 Nov 23;147(5):992-1009
references.pmid: 22118458
references.citation: Blood. 2011 Aug 25;118(8):2254-65
references.pmid: 21734236
references.citation: Nat Rev Immunol. 2004 Dec;4(12):941-52
references.pmid: 15573129
references.citation: Clin Exp Immunol. 1992 Mar;87(3):415-21
references.pmid: 1371955
references.citation: Cancer Res. 2012 Mar 15;72(6):1373-83
references.pmid: 22282665
references.citation: Curr Top Microbiol Immunol. 1999;238:57-78
references.pmid: 10087650
references.citation: Curr Opin Immunol. 2000 Oct;12(5):571-5
references.pmid: 11007361
references.citation: Vaccine. 2006 Mar 20;24(13):2264-74
references.pmid: 16376465
references.citation: Nat Med. 2002 Aug;8(8):793-800
references.pmid: 12091876
references.citation: Cancer Res. 2002 May 15;62(10):2869-74
references.pmid: 12019166
references.citation: J Immunol. 1985 Oct;135(4):2865-75
references.pmid: 2993418
references.citation: Annu Rev Immunol. 2007;25:267-96
references.pmid: 17134371
references.citation: Exp Mol Pathol. 2007 Feb;82(1):12-24
references.pmid: 16919266
references.citation: Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):10889-94
references.pmid: 9380730
references.citation: Clin Immunol. 2012 Sep;144(3):250-68
references.pmid: 22858650
references.citation: Hum Gene Ther. 1997 Dec 10;8(18):2217-28
references.pmid: 9449375
references.citation: Mol Ther. 2012 May;20(5):927-37
references.pmid: 22334018
references.citation: J Immunol. 2004 Oct 1;173(7):4352-9
references.pmid: 15383564